Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Metformin Gel Following Mandibular Third Molar Removal
NCT06975839Phase 2Not yet recruiting
- Sponsor
- Fayoum University
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of metformin 1% gel in Impacted Mandibular Third Molar (IM3M) (2 arms), sponsored by Fayoum University. Primary endpoint: Bone density at 6 months. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
metformin 1% gel
03
Conditions
Impacted Mandibular Third Molar (IM3M)
Beyond the preview
Go deeper on NCT06975839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975839.